Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate

Treatment With the Radiolabeled Somatostatin Analog [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Medicine, Nuclear Medicine, Oncology +17

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Michael G. Stabin, Richard Sparks, Eric A. Crowe · PubMed · 2005 · 1.4K citations

Medicine, Internal Medicine, Nuclear Medicine +14

Radiolabeled Somatostatin Analog [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Dik J. Kwekkeboom, Jaap J.M. Teunissen, Willem H. Bakker et al. · Journal of Clinical Oncology · 2005 · 659 citations · Full text

Medicine, Oncology, Pharmacology +15

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Dik J. Kwekkeboom, Willem H. Bakker, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 471 citations

Medicine, Endocrinology, Nuclear Medicine +3

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Dik J. Kwekkeboom, Jan Mueller‐Brand, Giovanni Paganelli et al. · PubMed · 2005 · 375 citations · Full text

Medicine, Nuclear Medicine, Oncology +17